Oral Terbinafine for Tinea Corporis
For adult tinea corporis, use oral terbinafine 250 mg once daily for 1-2 weeks, though emerging resistance patterns and poor cure rates in recent studies suggest this may be inadequate for many cases. 1
FDA-Approved Dosing
The FDA label for terbinafine does not specifically list tinea corporis as an approved indication—it is only approved for onychomycosis 1. However, terbinafine has extensive off-label use and research support for superficial dermatophyte infections.
Evidence-Based Dosing Recommendations
Standard Regimen
- Dose: 250 mg once daily
- Duration: 1-2 weeks for tinea corporis 2
- This represents the traditional approach supported by older literature
Ultra-Short Course Options
Historical studies demonstrated efficacy with remarkably brief courses:
- 1 week therapy: 250 mg daily for 7 days showed complete mycological clearance in all patients at 6-week follow-up 3
- 2-3 day therapy: Even 250 mg daily for just 2-3 consecutive days showed 47-67% mycological cure rates 4
Critical Caveats and Emerging Concerns
Poor Contemporary Efficacy
A 2023 randomized trial revealed alarming treatment failure rates 5:
- Only 25.9% mycological cure at 4 weeks with 250 mg daily
- Only 20% overall cure rate at study end
- Doubling the dose to 500 mg daily provided no additional benefit (33.3% cure rate, P=0.82)
- This suggests either resistant organisms or inadequate treatment duration
Terbinafine Resistance
Emerging resistance is a serious concern, particularly with certain strains:
- Trichophyton mentagrophytes genotype VIII (Indian genotype) shows point mutations in the SQLE gene conferring terbinafine resistance 6
- Trichophyton rubrum strains with I479T and I479V mutations demonstrate clinical resistance despite initial in vitro sensitivity 7
- These resistant strains are spreading globally due to international travel 6
Practical Algorithm
For treatment-naive tinea corporis in adults:
First-line: Terbinafine 250 mg daily for 4 weeks (not 1-2 weeks given poor contemporary cure rates) 5
- Consider adding topical antifungal (clotrimazole, miconazole) for synergy
If no improvement after 2 weeks or recurrence:
For extensive disease (>5% BSA):
- Consider starting with itraconazole 200-400 mg daily given better cure rates in recent trials 8
Monitoring and Safety
Baseline liver function tests are mandatory before initiating terbinafine due to risk of hepatotoxicity 1. Additional warnings include:
- Taste and smell disturbances (may be permanent)
- Severe neutropenia
- Stevens-Johnson syndrome/TEN
- Depressive symptoms 1
Relapse Rates
Expect high relapse rates (~47%) regardless of initial dose used 8. This necessitates:
- Follow-up at 4-8 weeks post-treatment
- Patient education about recurrence risk
- Consideration of longer treatment courses than historically recommended
The evidence suggests that traditional 1-2 week courses are insufficient in the current era of resistant dermatophytes, and 4-week courses with consideration of alternative agents like itraconazole should be the contemporary standard.